Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Indevr's AmpliPhox System

Premium

Indevr recently launched its AmpliPhox system for nucleic acid and protein microarray analysis.

AmpliPhox is based on Indevr's colorimetric detection technology. The approach relies on a photoinitiator that, when activated by light, generates signal amplification through polymerization of an organic monomer, according to the firm. The system's AmpliPhox Reader is used to activate photopolymerization on low-density arrays, to image the resulting pattern of visual spots, and automatically interpret the image.

The Boulder, Colo.-based company claims that results are delivered "within minutes" and are "visible to the naked eye."

Indevr claims that its detection technology, licensed from the University of Colorado, Boulder, enables it to offer the AmpliPhox Reader at "less than one-tenth the price of typical fluorescence microarray readers." The list price on the firm's website is $3,645. In comparison, ArrayIt advertises its SpotLight microarray scanner for $30,398.

Indevr CEO Kathy Rowlen said in a statement that the platform could be used for "a myriad of applications; everything from pathogen detection with nucleic acids to disease state profiling with proteins."

The company is currently offering free AmpliPhox systems to customers who purchase 10 reagent kits.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.